Imaging the pathophysiology of major depressive disorder - from localist models to circuit-based analysis

Biology of Mood & Anxiety Disorders

Michael T Treadway¹  Diego A Pizzagalli¹ 

[1] Center for Depression Anxiety and Stress Research, McLean Hospital/Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA

关键词: Inflammation;    GABA;    Glutamate;    MRS;    Dopamine;    Serotonin;    MRI;    PET;    Neuroimaging;    Major Depression;   

Others  :  791686
DOI  :  10.1186/2045-5380-4-5

 received in 2013-11-19, accepted in 2014-02-17,  发布年份 2014

【 摘 要 】

The neuroimaging literature of Major Depressive Disorder (MDD) has grown substantially over the last several decades, facilitating great advances in the identification of specific brain regions, neurotransmitter systems and networks associated with depressive illness. Despite this progress, fundamental questions remain about the pathophysiology and etiology of MDD. More importantly, this body of work has yet to directly influence clinical practice. It has long been a goal for the fields of clinical psychology and psychiatry to have a means of making objective diagnoses of mental disorders. Frustratingly little movement has been achieved on this front, however, and the 'gold-standard’ of diagnostic validity and reliability remains expert consensus. In light of this challenge, the focus of the current review is to provide a critical summary of key findings from different neuroimaging approaches in MDD research, including structural, functional and neurochemical imaging studies. Following this summary, we discuss some of the current conceptual obstacles to better understanding the pathophysiology of depression, and conclude with recommendations for future neuroimaging research.

【 授权许可】

   
2014 Treadway and Pizzagalli; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Kapur S, Phillips AG, Insel TR: Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry 2012, 17:1174-1179.
• [2]Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ, Hulshoff Pol HE, Kahn RS: Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp 2009.
• [3]Kempton MJ, Salvador Z, Munafo MR, Geddes JR, Simmons A, Frangou S, Williams SC: Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder. Arch Gen Psychiatry 2011, 68:675-690.
• [4]Bora E, Fornito A, Pantelis C, Yucel M: Gray matter abnormalities in Major Depressive Disorder: a meta-analysis of voxel based morphometry studies. J Affect Disord 2011, 138:9-18.
• [5]Cotter D, Mackay D, Landau S, Kerwin R, Everall I: Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 2001, 58:545-553.
• [6]Liao Y, Huang X, Wu Q, Yang C, Kuang W, Du M, Lui S, Yue Q, Chan RC, Kemp GJ, Gong Q: Is depression a disconnection syndrome? Meta-analysis of diffusion tensor imaging studies in patients with MDD. J Psychiatry Neurosci 2013, 38:49-56.
• [7]Yucel K, McKinnon MC, Chahal R, Taylor VH, Macdonald K, Joffe R, MacQueen GM: Anterior cingulate volumes in never-treated patients with major depressive disorder. Neuropsychopharmacology 2008, 33:3157-3163.
• [8]McKinnon MC, Yucel K, Nazarov A, MacQueen GM: A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci 2009, 34:41-54.
• [9]van Eijndhoven P, van Wingen G, van Oijen K, Rijpkema M, Goraj B, Jan Verkes R, Oude Voshaar R, Fernandez G, Buitelaar J, Tendolkar I: Amygdala volume marks the acute state in the early course of depression. Biol Psychiatry 2009, 65:812-818.
• [10]Frodl T, Meisenzahl EM, Zetzsche T, Hohne T, Banac S, Schorr C, Jager M, Leinsinger G, Bottlender R, Reiser M, Moller HJ: Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. J Clin Psychiatry 2004, 65:492-499.
• [11]Frodl T, Jager M, Smajstrlova I, Born C, Bottlender R, Palladino T, Reiser M, Moller HJ, Meisenzahl EM: Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. J Psychiatry Neurosci 2008, 33:423-430.
• [12]Arnone D, McKie S, Elliott R, Juhasz G, Thomas EJ, Downey D, Williams S, Deakin JF, Anderson IM: State-dependent changes in hippocampal grey matter in depression. Mol Psychiatry 2012.
• [13]Schermuly I, Wolf D, Lieb K, Stoeter P, Fellgiebel A: State dependent posterior hippocampal volume increases in patients with major depressive disorder. J Affect Disord 2011, 135:405-409.
• [14]Holmes AJ, Lee PH, Hollinshead MO, Bakst L, Roffman JL, Smoller JW, Buckner RL: Individual differences in amygdala-medial prefrontal anatomy link negative affect, impaired social functioning, and polygenic depression risk. J Neurosci 2012, 32:18087-18100.
• [15]Saleh K, Carballedo A, Lisiecka D, Fagan AJ, Connolly G, Boyle G, Frodl T: Impact of family history and depression on amygdala volume. Psychiatry Res 2012, 203:24-30.
• [16]Amico F, Meisenzahl E, Koutsouleris N, Reiser M, Moller HJ, Frodl T: Structural MRI correlates for vulnerability and resilience to major depressive disorder. J Psychiatry Neurosci 2011, 36:15-22.
• [17]Hasler G, Northoff G: Discovering imaging endophenotypes for major depression. Mol Psychiatry 2011, 16:604-619.
• [18]Diener C, Kuehner C, Brusniak W, Ubl B, Wessa M, Flor H: A meta-analysis of neurofunctional imaging studies of emotion and cognition in major depression. Neuroimage 2012, 61:677-685.
• [19]Hamilton JP, Etkin A, Furman DJ, Lemus MG, Johnson RF, Gotlib IH: Functional neuroimaging of major depressive disorder: a meta-analysis and new integration of base line activation and neural response data. Am J Psychiatry 2012, 169:693-703.
• [20]Pizzagalli DA: Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 2011, 36:183-206.
• [21]Victor TA, Furey ML, Fromm SJ, Ohman A, Drevets WC: Relationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder. Arch Gen Psychiatry 2010, 67:1128-1138.
• [22]Fu CH, Williams SC, Cleare AJ, Brammer MJ, Walsh ND, Kim J, Andrew CM, Pich EM, Williams PM, Reed LJ, Mitterschiffthaler MT, Suckling J, Bullmore ET: Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry 2004, 61:877-889.
• [23]Siegle GJ, Steinhauer SR, Thase ME, Stenger VA, Carter CS: Can’t shake that feeling: event-related fMRI assessment of sustained amygdala activity in response to emotional information in depressed individuals. Biol Psychiatry 2002, 51:693-707.
• [24]Mitterschiffthaler MT, Williams SC, Walsh ND, Cleare AJ, Donaldson C, Scott J, Fu CH: Neural basis of the emotional Stroop interference effect in major depression. Psychol Med 2008, 38:247-256.
• [25]Siegle GJ, Thompson W, Carter CS, Steinhauer SR, Thase ME: Increased amygdala and decreased dorsolateral prefrontal BOLD responses in unipolar depression: related and independent features. Biol Psychiatry 2007, 61:198-209.
• [26]Beauregard M, Paquette V, Levesque J: Dysfunction in the neural circuitry of emotional self-regulation in major depressive disorder. Neuroreport 2006, 17:843-846.
• [27]Dillon DG, Pizzagalli DA: Evidence of successful modulation of brain activation and subjective experience during reappraisal of negative emotion in unmedicated depression. Psychiatry Res 2013, 212:99-107.
• [28]Erk S, Mikschl A, Stier S, Ciaramidaro A, Gapp V, Weber B, Walter H: Acute and sustained effects of cognitive emotion regulation in major depression. J Neurosci 2010, 30:15726-15734.
• [29]Johnstone T, van Reekum CM, Urry HL, Kalin NH, Davidson RJ: Failure to regulate: counterproductive recruitment of top-down prefrontal-subcortical circuitry in major depression. J Neurosci 2007, 27:8877-8884.
• [30]Matsuo K, Glahn DC, Peluso MA, Hatch JP, Monkul ES, Najt P, Sanches M, Zamarripa F, Li J, Lancaster JL, Fox PT, Gao JH, Soares JC: Prefrontal hyperactivation during working memory task in untreated individuals with major depressive disorder. Mol Psychiatry 2007, 12:158-166.
• [31]Wagner G, Sinsel E, Sobanski T, Kohler S, Marinou V, Mentzel HJ, Sauer H, Schlosser RG: Cortical inefficiency in patients with unipolar depression: an event-related FMRI study with the Stroop task. Biol Psychiatry 2006, 59:958-965.
• [32]Etkin A, Schatzberg AF: Common abnormalities and disorder-specific compensation during implicit regulation of emotional processing in generalized anxiety and major depressive disorders. Am J Psychiatry 2011, 168:968-978.
• [33]Beesdo K, Lau JY, Guyer AE, McClure-Tone EB, Monk CS, Nelson EE, Fromm SJ, Goldwin MA, Wittchen HU, Leibenluft E, Ernst M, Pine DS: Common and distinct amygdala-function perturbations in depressed versus anxious adolescents. Arch Gen Psychiatry 2009, 66:275-285.
• [34]Ochsner KN, Ray RD, Cooper JC, Robertson ER, Chopra S, Gabrieli JD, Gross JJ: For better or for worse: neural systems supporting the cognitive down- and up-regulation of negative emotion. Neuroimage 2004, 23:483-499.
• [35]Matthews SC, Strigo IA, Simmons AN, Yang TT, Paulus MP: Decreased functional coupling of the amygdala and supragenual cingulate is related to increased depression in unmedicated individuals with current major depressive disorder. J Affect Disord 2008, 111:13-20.
• [36]Mitterschiffthaler MT, Kumari V, Malhi GS, Brown RG, Giampietro VP, Brammer MJ, Suckling J, Poon L, Simmons A, Andrew C, Sharma T: Neural response to pleasant stimuli in anhedonia: an fMRI study. Neuroreport 2003, 14:177-182.
• [37]Surguladze S, Brammer MJ, Keedwell P, Giampietro V, Young AW, Travis MJ, Williams SC, Phillips ML: A differential pattern of neural response toward sad versus happy facial expressions in major depressive disorder. Biol Psychiatry 2005, 57:201-209.
• [38]Keedwell PA, Andrew C, Williams SC, Brammer MJ, Phillips ML: A double dissociation of ventromedial prefrontal cortical responses to sad and happy stimuli in depressed and healthy individuals. Biol Psychiatry 2005, 58:495-503.
• [39]Gotlib IH, Hamilton JP, Cooney RE, Singh MK, Henry ML, Joormann J: Neural processing of reward and loss in girls at risk for major depression. Arch Gen Psychiatry 2010, 67:380-387.
• [40]Dichter GS, Felder JN, Petty C, Bizzell J, Ernst M, Smoski MJ: The effects of psychotherapy on neural responses to rewards in major depression. Biol Psychiatry 2009, 66:886-897.
• [41]Forbes EE, Hariri AR, Martin SL, Silk JS, Moyles DL, Fisher PM, Brown SM, Ryan ND, Birmaher B, Axelson DA, Dahl RE: Altered striatal activation predicting real-world positive affect in adolescent major depressive disorder. Am J Psychiatry 2009, 166:64-73.
• [42]Pizzagalli DA, Holmes AJ, Dillon DG, Goetz EL, Birk JL, Bogdan R, Dougherty DD, Iosifescu DV, Rauch SL, Fava M: Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry 2009, 166:702-710.
• [43]Kumar P, Waiter G, Ahearn T, Milders M, Reid I, Steele JD: Abnormal temporal difference reward-learning signals in major depression. Brain 2008, 131:2084-2093.
• [44]Pizzagalli DA, Iosifescu D, Hallett LA, Ratner KG, Fava M: Reduced hedonic capacity in major depressive disorder: evidence from a probabilistic reward task. J Psychiatr Res 2008, 43:76-87.
• [45]Clery-Melin ML, Schmidt L, Lafargue G, Baup N, Fossati P, Pessiglione M: Why don’t you try harder? An investigation of effort production in major depression. PLoS One 2011, 6:e23178.
• [46]Sherdell L, Waugh CE, Gotlib IH: Anticipatory pleasure predicts motivation for reward in major depression. J Abnorm Psychol 2011.
• [47]Treadway MT, Bossaller NA, Shelton RC, Zald DH: Effort-based decision-making in major depressive disorder: a translational model of motivational anhedonia. J Abnorm Psychol 2012.
• [48]Berridge KC: The debate over dopamine’s role in reward: the case for incentive salience. Psychopharmacology (Berl) 2007, 191:391-431.
• [49]Treadway MT, Zald DH: Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev 2011, 35:537-555.
• [50]Capuron L, Pagnoni G, Drake DF, Woolwine BJ, Spivey JR, Crowe RJ, Votaw JR, Goodman MM, Miller AH: Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch Gen Psychiatry 2012, 69:1044-1053.
• [51]Hasler G, Fromm S, Carlson PJ, Luckenbaugh DA, Waldeck T, Geraci M, Roiser JP, Neumeister A, Meyers N, Charney DS, Drevets WC: Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch Gen Psychiatry 2008, 65:521-531.
• [52]Hasler G, Luckenbaugh DA, Snow J, Meyers N, Waldeck T, Geraci M, Roiser J, Knutson B, Charney DS, Drevets WC: Reward processing after catecholamine depletion in unmedicated, remitted subjects with major depressive disorder. Biol Psychiatry 2009, 66:201-205.
• [53]Heller AS, Johnstone T, Shackman AJ, Light SN, Peterson MJ, Kolden GG, Kalin NH, Davidson RJ: Reduced capacity to sustain positive emotion in major depression reflects diminished maintenance of fronto-striatal brain activation. Proc Natl Acad Sci U S A 2009, 106:22445-22450.
• [54]Schildkraut JJ: The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965, 122:509-522.
• [55]Jacobs BL, Fornal CA: Activity of serotonergic neurons in behaving animals. Neuropsychopharmacology 1999, 21:9S-15S.
• [56]Daubert EA, Condron BG: Serotonin: a regulator of neuronal morphology and circuitry. Trends Neurosci 2010, 33:424-434.
• [57]Jasinska AJ, Lowry CA, Burmeister M: Serotonin transporter gene, stress and raphe-raphe interactions: a molecular mechanism of depression. Trends Neurosci 2012, 35:395-402.
• [58]Amat J, Baratta MV, Paul E, Bland ST, Watkins LR, Maier SF: Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. Nat Neurosci 2005, 8:365-371.
• [59]Amat J, Paul E, Watkins LR, Maier SF: Activation of the ventral medial prefrontal cortex during an uncontrollable stressor reproduces both the immediate and long-term protective effects of behavioral control. Neuroscience 2008, 154:1178-1186.
• [60]Hammen C: Stress and depression. Annu Rev Clin Psychol 2005, 1:293-319.
• [61]Kessler RC: The effects of stressful life events on depression. Annu Rev Psychol 1997, 48:191-214.
• [62]Kendler KS, Karkowski LM, Prescott CA: Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry 1999, 156:837-841.
• [63]Savitz JB, Drevets WC: Neuroreceptor imaging in depression. Neurobiol Dis 2013, 52:49-65.
• [64]Smith DF, Jakobsen S: Molecular neurobiology of depression: PET findings on the elusive correlation with symptom severity. Front Psychiatry 2013, 4:8.
• [65]Willner P: Dopamine and depression: a review of recent evidence. I. Empirical studies. Brain Res 1983, 287:211-224.
• [66]van Praag HM, Korf J, Schut D: Cerebral monoamines and depression. An investigation with the probenecid technique. Arch Gen Psychiatry 1973, 28:827-831.
• [67]Salamone JD, Correa M: The mysterious motivational functions of mesolimbic dopamine. Neuron 2012, 76:470-485.
• [68]Schultz W: Behavioral dopamine signals. Trends Neurosci 2007, 30:203-210.
• [69]Barch DM, Dowd EC: Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions. Schizophr Bull 2010, 36:919-934.
• [70]Treadway MT, Zald DH: Parsing anhedonia translational models of reward-processing deficits in psychopathology. Curr Dir Psychol Sci 2013, 22:244-249.
• [71]Agren H, Reibring L: PET studies of presynaptic monoamine metabolism in depressed patients and healthy volunteers. Pharmacopsychiatry 1994, 27:2-6.
• [72]Meyer JH, Kruger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A, Minifie C, Houle S, Hussey D, Kennedy SH: Lower dopamine transporter binding potential in striatum during depression. Neuroreport 2001, 12:4121-4125.
• [73]Yang YK, Yeh TL, Yao WJ, Lee IH, Chen PS, Chiu NT, Lu RB: Greater availability of dopamine transporters in patients with major depression - a dual-isotope SPECT study. Psychiatry Res 2008, 162:230-235.
• [74]Amsterdam JD, Newberg AB: A preliminary study of dopamine transporter binding in bipolar and unipolar depressed patients and healthy controls. Neuropsychobiology 2007, 55:167-170.
• [75]Laasonen-Balk T, Kuikka J, Viinamaki H, Husso-Saastamoinen M, Lehtonen J, Tiihonen J: Striatal dopamine transporter density in major depression. Psychopharmacology (Berl) 1999, 144:282-285.
• [76]Rahmim A, Zaidi H: PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun 2008, 29:193-207.
• [77]Klimek V, Schenck JE, Han H, Stockmeier CA, Ordway GA: Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiatry 2002, 52:740-748.
• [78]Shah PJ, Ogilvie AD, Goodwin GM, Ebmeier KP: Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol Med 1997, 27:1247-1256.
• [79]D’Haenen HA, Bossuyt A: Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry 1994, 35:128-132.
• [80]Gershon AA, Vishne T, Grunhaus L: Dopamine D2-like receptors and the antidepressant response. Biol Psychiatry 2007, 61:145-153.
• [81]Parsey RV, Oquendo MA, Zea-Ponce Y, Rodenhiser J, Kegeles LS, Pratap M, Cooper TB, Van Heertum R, Mann JJ, Laruelle M: Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry 2001, 50:313-322.
• [82]Hirvonen J, Karlsson H, Kajander J, Markkula J, Rasi-Hakala H, Nagren K, Salminen JK, Hietala J: Striatal dopamine D2 receptors in medication-naive patients with major depressive disorder as assessed with [11C]raclopride PET. Psychopharmacology (Berl) 2008, 197:581-590.
• [83]Klimke A, Larisch R, Janz A, Vosberg H, Muller-Gartner HW, Gaebel W: Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT. Psychiatry Res 1999, 90:91-101.
• [84]Cannon DM, Klaver JM, Peck SA, Rallis-Voak D, Erickson K, Drevets WC: Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112. Neuropsychopharmacology 2009, 34:1277-1287.
• [85]Sarchiapone M, Carli V, Camardese G, Cuomo C, Di Giuda D, Calcagni ML, Focacci C, De Risio S: Dopamine transporter binding in depressed patients with anhedonia. Psychiatry Res 2006, 147:243-248.
• [86]Martinot M, Bragulat V, Artiges E, Dolle F, Hinnen F, Jouvent R, Martinot J: Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am J Psychiatry 2001, 158:314-316.
• [87]Bragulat V, Paillere-Martinot ML, Artiges E, Frouin V, Poline JB, Martinot JL: Dopaminergic function in depressed patients with affective flattening or with impulsivity: [18 F]fluoro-L-dopa positron emission tomography study with voxel-based analysis. Psychiatry Res 2007, 154:115-124.
• [88]Haroon E, Raison CL, Miller AH: Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2011, 37:137-162.
• [89]Takano H, Arakawa R, Nogami T, Suzuki M, Nagashima T, Fujiwara H, Kimura Y, Kodaka F, Takahata K, Shimada H: Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S, S)-[18F] FMeNER-D2. Int J Neuropsychopharmaco 2013, 1-8.
• [90]van Wingen GA, Tendolkar I, Urner M, van Marle H, Denys D, Verkes R-J, Fernandez G: Short-term antidepressant administration reduces default mode and task-positive network connectivity in healthy individuals during rest. Neuroimage 2013.
• [91]Ossewaarde L, Verkes RJ, Hermans EJ, Kooijman SC, Urner M, Tendolkar I, van Wingen GA, Fernandez G: Two-week administration of the combined serotonin-noradrenaline reuptake inhibitor duloxetine augments functioning of mesolimbic incentive processing circuits. Biol Psychiatry 2011, 70:568-574.
• [92]Bruhl AB, Jancke L, Herwig U: Differential modulation of emotion processing brain regions by noradrenergic and serotonergic antidepressants. Psychopharmacology (Berl) 2011, 216:389-399.
• [93]Bruhl AB, Kaffenberger T, Herwig U: Serotonergic and noradrenergic modulation of emotion processing by single dose antidepressants. Neuropsychopharmacology 2010, 35:521.
• [94]Ressler KJ, Nemeroff CB: Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiatry 1999, 46:1219-1233.
• [95]Sanacora G, Treccani G, Popoli M: Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012, 62:63-77.
• [96]Altamura CA, Mauri MC, Ferrara A, Moro AR, D’Andrea G, Zamberlan F: Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 1993, 150:1731-1733.
• [97]Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH: Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr 1982, 232:299-304.
• [98]Hashimoto K, Sawa A, Iyo M: Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007, 62:1310-1316.
• [99]Yuksel C, Ongur D: Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry 2010, 68:785-794.
• [100]Luykx JJ, Laban KG, van den Heuvel MP, Boks MP, Mandl RC, Kahn RS, Bakker SC: Region and state specific glutamate downregulation in major depressive disorder: a meta-analysis of (1)H-MRS findings. Neurosci Biobehav Rev 2011, 36:198-205.
• [101]Jarnum H, Eskildsen SF, Steffensen EG, Lundbye-Christensen S, Simonsen CW, Thomsen IS, Frund ET, Theberge J, Larsson EM: Longitudinal MRI study of cortical thickness, perfusion, and metabolite levels in major depressive disorder. Acta Psychiatr Scand 2011, 124:435-446.
• [102]Portella MJ, de Diego-Adelino J, Gomez-Anson B, Morgan-Ferrando R, Vives Y, Puigdemont D, Perez-Egea R, Ruscalleda J, Enric A, Perez V: Ventromedial prefrontal spectroscopic abnormalities over the course of depression: a comparison among first episode, remitted recurrent and chronic patients. J Psychiatr Res 2010, 45:427-434.
• [103]Merkl A, Schubert F, Quante A, Luborzewski A, Brakemeier EL, Grimm S, Heuser I, Bajbouj M: Abnormal cingulate and prefrontal cortical neurochemistry in major depression after electroconvulsive therapy. Biol Psychiatry 2010, 69:772-779.
• [104]Kondo DG, Hellem TL, Sung YH, Kim N, Jeong EK, Delmastro KK, Shi X, Renshaw PF: Review: magnetic resonance spectroscopy studies of pediatric major depressive disorder. Depress Res Treat 2011, 2011:650450.
• [105]Deschwanden A, Karolewicz B, Feyissa AM, Treyer V, Ametamey SM, Johayem A, Burger C, Auberson YP, Sovago J, Stockmeier CA, Buck A, Hasler G: Reduced metabotropic glutamate receptor 5 density in major depression determined by [11C]ABP688 PET and postmortem study. Am J Psychiatry 2011, 168:727-734.
• [106]Hefti K, Holst SC, Sovago J, Bachmann V, Buck A, Ametamey SM, Scheidegger M, Berthold T, Gomez-Mancilla B, Seifritz E: Increased metabotropic glutamate receptor subtype 5 availability in human brain after one night without sleep. Biol Psychiatry 2013.
• [107]Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
• [108]Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.
• [109]Luscher B, Shen Q, Sahir N: The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry 2010, 16:383-406.
• [110]Petty F, Schlesser MA: Plasma GABA in affective illness. A preliminary investigation. J Affect Disord 1981, 3:339-343.
• [111]Petty F, Sherman AD: GABAergic modulation of learned helplessness. Pharmacol Biochem Behav 1981, 15:567-570.
• [112]Gerner RH, Hare TA: CSF GABA in normal subjects and patients with depression, schizophrenia, mania, and anorexia nervosa. Am J Psychiatry 1981, 138:1098-1101.
• [113]Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC: Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2007, 64:193-200.
• [114]Gabbay V, Mao X, Klein RG, Ely BA, Babb JS, Panzer AM, Alonso CM, Shungu DC: Anterior cingulate cortex gamma-aminobutyric acid in depressed adolescents: relationship to anhedonia. Arch Gen Psychiatry 2012, 69:139-149.
• [115]Radley JJ, Sawchenko PE: A common substrate for prefrontal and hippocampal inhibition of the neuroendocrine stress response. J Neurosci 2011, 31:9683-9695.
• [116]Radley JJ, Gosselink KL, Sawchenko PE: A discrete GABAergic relay mediates medial prefrontal cortical inhibition of the neuroendocrine stress response. J Neurosci 2009, 29:7330-7340.
• [117]Homan P, Drevets WC, Hasler G: Neural correlates of free T3 alteration after catecholamine depletion in subjects with remitted major depressive disorder and in controls. Psychopharmacology (Berl) 2014, 231:409-417.
• [118]Homan P, Grob S, Milos G, Schnyder U, Hasler G: Reduction in total plasma ghrelin levels following catecholamine depletion: relation to bulimic and depressive symptoms. Psychoneuroendocrinology 2013.
• [119]McEwen BS: Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007, 87:873-904.
• [120]Sapolsky RM: Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000, 57:925-935.
• [121]Radley JJ, Rocher AB, Miller M, Janssen WG, Liston C, Hof PR, McEwen BS, Morrison JH: Repeated stress induces dendritic spine loss in the rat medial prefrontal cortex. Cereb Cortex 2006, 16:313-320.
• [122]Cook SC, Wellman CL: Chronic stress alters dendritic morphology in rat medial prefrontal cortex. J Neurobiol 2004, 60:236-248.
• [123]Cerqueira JJ, Pego JM, Taipa R, Bessa JM, Almeida OF, Sousa N: Morphological correlates of corticosteroid-induced changes in prefrontal cortex-dependent behaviors. J Neurosci 2005, 25:7792-7800.
• [124]McEwen BS: Stress and hippocampal plasticity. Annu Rev Neurosci 1999, 22:105-122.
• [125]Treadway MT, Grant MM, Ding Z, Hollon SD, Gore JC, Shelton RC: Early adverse events, HPA activity and rostral anterior cingulate volume in MDD. PLoS One 2009, 4:e4887.
• [126]Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL: A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67:446-457.
• [127]Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, McCorkle R, Seligman DA, Schmidt K: The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001, 15:199-226.
• [128]Shelton RC, Miller AH: Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression. Prog Neurobiol 2010, 91:275-299.
• [129]Papakostas GI, Shelton RC, Kinrys G, Henry ME, Bakow BR, Lipkin SH, Pi B, Thurmond L, Bilello JA: Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a Pilot and Replication Study. Mol Psychiatry 2011.
• [130]Miller AH, Maletic V, Raison CL: Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65:732-741.
• [131]Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
• [132]Dantzer R, Meagher MW, Cleeland CS: Translational approaches to treatment-induced symptoms in cancer patients. Nat Rev Clin Oncol 2012, 9:414-426.
• [133]Felger JC, Mun J, Kimmel HL, Nye JA, Drake DF, Hernandez CR, Freeman AA, Rye DB, Goodman MM, Howell LL: Chronic interferon-α decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates. Neuropsychopharmacology 2013.
• [134]Felger JC, Alagbe O, Hu F, Mook D, Freeman AA, Sanchez MM, Kalin NH, Ratti E, Nemeroff CB, Miller AH: Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression. Biol Psychiatry 2007, 62:1324-1333.
• [135]Nunes EJ, Randall PA, Estrada A, Epling B, Hart EE, Lee CA, Baqi Y, Mueller CE, Correa M, Salamone JD: Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/chow feeding choice task. Psychopharmacology (Berl) 2014, 231:727-736.
• [136]Hannestad J, DellaGioia N, Gallezot J-D, Lim K, Nabulsi N, Esterlis I, Pittman B, Lee J-YO, Pelletier D, ÄôConnor KC: The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: A [< sup > 11 C] PBR28 PET study. Brain Behav Immun 2013, 33:131-138.
• [137]Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR: Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry 2010, 68:748-754.
• [138]McGrath CL, Kelley ME, Holtzheimer PE, Dunlop BW, Craighead WE, Franco AR, Craddock RC, Mayberg HS: Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry 2013, 70:821-829.
• [139]Malone DA Jr, Dougherty DD, Rezai AR, Carpenter LL, Friehs GM, Eskandar EN, Rauch SL, Rasmussen SA, Machado AG, Kubu CS, Tyrka AR, Price LH, Stypulkowski PH, Giftakis JE, Rise MT, Malloy PF, Salloway SP, Greenberg BD: Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry 2009, 65:267-275.
• [140]Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, Schwalb JM, Kennedy SH: Deep brain stimulation for treatment-resistant depression. Neuron 2005, 45:651-660.
• [141]Carpenter LL, Janicak PG, Aaronson ST, Boyadjis T, Brock DG, Cook IA, Dunner DL, Lanocha K, Solvason HB, Demitrack MA: Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety 2012, 29:587-596.
• [142]Raison CL, Miller AH: Is depression an inflammatory disorder? Curr Psychiatry Rep 2011, 13:467-475.
• [143]Cooper JC, Bloom FE, Roth RH: The Biochemical Basis of Neuropharmacology. 8th edition. New York: Oxford University Press; 2003.
• [144]Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, Sanislow C, Wang P: Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010, 167:748-751.
• [145]Akil H, Brenner S, Kandel E, Kendler KS, King MC, Scolnick E, Watson JD, Zoghbi HY: Medicine. The future of psychiatric research: genomes and neural circuits. Science 2010, 327:1580-1581.
• [146]Nestler EJ, Hyman SE: Animal models of neuropsychiatric disorders. Nat Neurosci 2010, 13:1161-1169.
• [147]Deisseroth K: Circuit dynamics of adaptive and maladaptive behaviour. Nature 2014, 505:309-317.
• [148]Bullmore ET, Bassett DS: Brain graphs: graphical models of the human brain connectome. Annu Rev Clin Psychol 2011, 7:113-14.
• [149]Bullmore E, Sporns O: Complex brain networks: graph theoretical analysis of structural and functional systems. Nat Rev Neurosci 2009, 10:186-198.
• [150]Buckholtz JW, Meyer-Lindenberg A: Psychopathology and the human connectome: toward a transdiagnostic model of risk for mental illness. Neuron 2012, 74:990-1004.
• [151]Friston KJ, Ashburner JT, Kiebel SJ, Nichols TE, Penny WD: Statistical Parametric Mapping: the Analysis of Functional Brain Images. Academic; 2011.
• [152]Walter M, Henning A, Grimm S, Schulte RF, Beck J, Dydak U, Schnepf B, Boeker H, Boesiger P, Northoff G: The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression. Arch Gen Psychiatry 2009, 66:478-486.
• [153]Kring AM, Sloan DM: Emotion Regulation and Psychopathology: a Transdiagnostic Approach to Etiology and Treatment. New York, NY: The Guilford Press; 2010.
• [154]Tremblay LK, Naranjo CA, Cardenas L, Herrmann N, Busto UE: Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. Arch Gen Psychiatry 2002, 59:409-416.
• [155]Tremblay LK, Naranjo CA, Graham SJ, Herrmann N, Mayberg HS, Hevenor S, Busto UE: Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch Gen Psychiatry 2005, 62:1228-1236.
• [156]Kahneman D, Riis J: Living, and thinking about it: two perspectives on life. In The science of well-being. Edited by Huppert FA, Baylis N, Keverne B. New York, NY: Oxford University Press; 2005.
• [157]Conner TS, Barrett LF: Trends in ambulatory self-report: the role of momentary experience in psychosomatic medicine. Psychosom Med 2012, 74:327-337.
• [158]Kahneman D, Krueger AB, Schkade D, Schwarz N, Stone AA: Would you be happier if you were richer? A focusing illusion. Science 2006, 312:1908-1910.
• [159]Kahneman D, Deaton A: High income improves evaluation of life but not emotional well-being. Proc Natl Acad Sci 2010, 107:16489-16493.
• [160]Schwarz N: Retrospective and concurrent self-reports: the rationale for real-time data capture. In The Science of Real-Time Data Caputre: Self-Reports in Health Research. Google e-book; 2007:11-26.
• [161]Strauss GP, Gold JM: A new perspective on anhedonia in schizophrenia. Am J Psychiatry 2012.
• [162]Kagan J: A trio of concerns. Perspect Psychol Sci 2007, 2:361-376.
• [163]Beck AT, Haigh E: The generic cognitive model. Annu Rev Clin Psychol 2013., 10